Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 7/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378770 | 0.91 | CA1 (0.58) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL17925349 | 0.90 | HTT (0.51) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL3928470 | 0.86 | ALDH1A1 (0.53) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL316883 | 0.85 | CA1 (0.66) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL11538899 | 0.85 | CA1 (0.52) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL5424654 | 0.85 | LTA4H (0.55) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL7416290 | 0.84 | CA1 (0.55) | HTTCA1CA2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL27650576 | 0.84 | LTA4H (0.54) | HTTCA1CA2ALDH1A1MAPK1 | |
| SCHEMBL7150639 | 0.84 | LTA4H (0.56) | CA1CA2ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7695939 | 0.84 | ALDH1A1 (0.66) | CA1CA2ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344461-B1 | SALTS OF ISOBUTYRIC ACID (1R*,2R*,4R*)-2-(2-{[3-(4,7-DIMETHOXY-1 H-BENZOIMIDAZOL-2-YL)-PROPYL]-METHYL-AMINO}-ETHYL)-5-PHENYL-BICYCLO[2.2.2]OCT-5-EN-2-YL ESTER | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8492555-B2 | Salts of isobutyric acid (1 R*, 2R*, 4R*)-2-(2-{[3-(4,7-dimethoxy-1 H-benzoimidazol-2-yl)-methyl-amino}-ethyl)-5-phenyl-bicyclo[2.2.2]oct-5-en-2-yl ester | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-07-23 | — | — | US | disclosed |
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263667-A1 | SALTS OF ISOBUTYRIC ACID (1 R*,2R*,4R*) -2- (2- - ETHYL)-5-PHENYL-BICYCLO [2.2.2] OCT-5-EN-2-YL | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2350021-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2344461-A1 | SALTS OF ISOBUTYRIC ACID (1 R*, 2R*, 4R* ) -2- (2-{ [3- (4, 7-DIMETH0XY-1 H-BENZOIMIDAZOL-2-YL) -PROPYL]-METHYL-AMINO } -ETHYL) -5-PHENYL-BICYCLO [2.2.2]OCT-5- EN- 2 -YL | Actelion Pharmaceuticals Ltd. (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-20110039905-A1 | BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
| EP-2271628-A1 | BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| WO-2010046857-A1 | SALTS OF ISOBUTYRIC ACID (1 R*, 2R*, 4R* ) -2- (2-{ [3- (4, 7-DIMETH0XY-1 H-BENZOIMIDAZOL-2-YL) -PROPYL] -METHYL-AMINO } -ETHYL) -5-PHENYL-BICYCLO [2.2.2] OCT-5- EN- 2 -YL | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046855-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-29 | — | — | WO | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009130679-A1 | BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-29 | — | — | WO | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | HTT 809/4885CA1 1070/4885CA2 163/4885 |
| US-20110039905-A1 | BENZIMIDAZOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, KCNN4, KCNN3 | HTT 3421/4885CA1 416/4885CA2 52/4885 |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | HTT 2887/4885CA1 571/4885CA2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.